Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years

NCT04450498 is registered in ClinicalTrials.gov with Walvax Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04450498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04450498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years
Lead sponsor
Walvax Biotechnology Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
December 23, 2020
Completion date
July 30, 2021
Enrollment
260 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neisseria meningitides meningitis